Marshall University - - Huntington, WV Huntington, WV
Ibrahim Shanti, MD1, Malik Samardali, MD2, Abdul Muhsen Abdeen, MD2, Tejas Joshi, MD3, Hafiz Ikram, MD2, Wesam Frandah, MD3, Ahmed Sherif, MD3 1Marshall University - - Huntington, WV, Huntington, WV; 2Joan C. Edwards School of Medicine, Marshall University, Huntington, WV; 3Marshall University Joan C. Edwards School of Medicine, Huntington, WV
Introduction: Background. Portal hypertension is a common consequence in cirrhosis and can cause variceal bleeding, ascites and hepatic encephalopathy. It is defined as elevation of hepatic venous pressure gradient (HVPG) >5 mmHg. Statins may enhance HVPG in patients with liver cirrhosis (LC).
This meta-analysis aimed to assess the impact of statins use on HVPG among patients suffering from LC.
Methods: Methods. We systematically searched seven databases to extract relevant papers. Version 2 of the Cochrane risk-of-bias tool for randomized trials (RoB 2) was used to assess the risk of bias for randomized controlled trials. The statistical analyses were carried out using Comprehensive Meta-Analysis version 3 (Biostat Inc., USA). Standard mean difference (SMD) with 95% confidence intervals (CIs) was calculated for hepatic venous pressure gradient using random effects.
Results: Results. The literature search found seven randomized controlled trials (RCT). Among the included studies, two were regarded as having a high risk of bias, while one study presented some concerns. However, four studies were rated as having a low risk of bias. Our results showed that statin treatment could significantly decrease the value HVPG comparing with control group (SMD: -0,613; 95% CI: -1,179 to -0,046; p = 0,034) as presented by the forest plot analysis. However, a high heterogeneity was detected among studies: Chi2 = 34,28, p = 0,000, I2 = 82%.
Discussion: Conclusions. This meta-analysis suggested that statins decreased HVPG and improved liver function in patients with cirrhosis. But, the beneficial effects of statins should be confirmed in long-term clinical trials for portal hypertension.
Figure: Figure 1-Our results showed that statin treatment could significantly decrease the value HVPG comparing with control group (SMD: -0,613; 95% CI: -1,179 to -0,046; p = 0,034) as presented by the forest plot analysis. However, a high heterogeneity was detected among studies: Chi2 = 34,28, p = 0,000, I2 = 82% .
Disclosures:
Ibrahim Shanti indicated no relevant financial relationships.
Malik Samardali indicated no relevant financial relationships.
Abdul Muhsen Abdeen indicated no relevant financial relationships.
Hafiz Ikram indicated no relevant financial relationships.
Wesam Frandah: Boston Scientific – Advisor or Review Panel Member, Consultant. Merritt – Consultant. Olympus corporation of America – Consultant.
Ahmed Sherif indicated no relevant financial relationships.
Ibrahim Shanti, MD1, Malik Samardali, MD2, Abdul Muhsen Abdeen, MD2, Tejas Joshi, MD3, Hafiz Ikram, MD2, Wesam Frandah, MD3, Ahmed Sherif, MD3. P5844 - A Meta-Analysis About the Efficacy of Statins on Hepatic Venous Pressure Gradient (HVPG) in Cirrhosis Disease, ACG 2025 Annual Scientific Meeting Abstracts. Phoenix, AZ: American College of Gastroenterology.